Mustang Bio Yönetim

Yönetim kriter kontrolleri 2/4

Mustang Bio CEO'su Manny Litchman, Apr2017 tarihinde atandı, in görev süresi 6.25 yıldır. in toplam yıllık tazminatı $ 656.67K olup, şirket hissesi ve opsiyonları dahil olmak üzere 71.3% maaş ve 28.7% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1.31% ine doğrudan sahiptir ve bu hisseler € 603.68K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2 yıl ve 7.1 yıldır.

Anahtar bilgiler

Manny Litchman

İcra Kurulu Başkanı

US$656.7k

Toplam tazminat

CEO maaş yüzdesi	71.3%
CEO görev süresi	6.3yrs
CEO sahipliği	1.3%
Yönetim ortalama görev süresi	2yrs
Yönetim Kurulu ortalama görev süresi	7.1yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Manny Litchman'un ücretlendirmesi Mustang Bio'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Mar 31 2023	n/a	n/a	-US$74m
Dec 31 2022	US$657k	US$468k	-US$78m
Sep 30 2022	n/a	n/a	-US$78m
Jun 30 2022	n/a	n/a	-US$76m
Mar 31 2022	n/a	n/a	-US$71m
Dec 31 2021	US$885k	US$450k	-US$66m
Sep 30 2021	n/a	n/a	-US$67m
Jun 30 2021	n/a	n/a	-US$63m
Mar 31 2021	n/a	n/a	-US$63m
Dec 31 2020	US$1m	US$430k	-US$60m
Sep 30 2020	n/a	n/a	-US$56m
Jun 30 2020	n/a	n/a	-US$53m
Mar 31 2020	n/a	n/a	-US$49m
Dec 31 2019	US$517k	US$415k	-US$46m
Sep 30 2019	n/a	n/a	-US$42m
Jun 30 2019	n/a	n/a	-US$39m
Mar 31 2019	n/a	n/a	-US$34m
Dec 31 2018	US$606k	US$403k	-US$31m
Sep 30 2018	n/a	n/a	-US$34m
Jun 30 2018	n/a	n/a	-US$34m
Mar 31 2018	n/a	n/a	-US$34m
Dec 31 2017	US$6m	US$267k	-US$31m

Tazminat ve Piyasa: Manny 'nin toplam tazminatı ($USD 656.67K ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 476.59K ).

Tazminat ve Kazançlar: Manny 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Manny Litchman (69 yo)

6.3yrs

Görev süresi

US$656,672

Tazminat

Dr. Manuel Litchman, also known as Manny, M.D. has been the President, Chief Executive Officer and Director at Mustang Bio Inc. since April 24, 2017. Dr. Litchman served as the Chief Executive Officer and...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Michael Weiss	Executive Chairman	8.2yrs	US$110.00k	0.11% € 51.5k
Manuel Litchman	President	6.3yrs	US$656.67k	1.31% € 603.7k
Eliot Lurier	Interim Chief Financial Officer	1.3yrs	US$282.83k	Veri yok
Greg Furrow	Interim CTO	less than a year	Veri yok	Veri yok
Matthew Wein	VP & General Counsel	1.8yrs	Veri yok	Veri yok
Debra Manning	Senior Vice President of Human Resources	4.5yrs	Veri yok	Veri yok
Bruce Dezube	Senior VP & Head of Clinical Development	2.1yrs	Veri yok	Veri yok
Rick Bodmer	VP & Head of CMC Development	less than a year	Veri yok	Veri yok
Robyn Hunter	Corporate Secretary	no data	Veri yok	Veri yok

2.0yrs

Ortalama Görev Süresi

63yo

Ortalama Yaş

Deneyimli Yönetim: 2W60 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 2 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Michael Weiss	Executive Chairman	8.2yrs	US$110.00k	0.11% € 51.5k
Manuel Litchman	President	6.3yrs	US$656.67k	1.31% € 603.7k
Lindsay Rosenwald	Non-Executive Director	8.3yrs	US$100.00k	0.25% € 113.5k
Michael Zelefsky	Independent Director	6.1yrs	US$100.00k	0.14% € 66.7k
Neil Herskowitz	Independent & Non-Executive Director	7.9yrs	US$100.00k	0.15% € 70.9k
Adam Chill	Independent Director	6.1yrs	US$110.00k	0.15% € 67.9k

7.1yrs

Ortalama Görev Süresi

64.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 2W60 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.1 yıldır).

Mustang Bio Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Mustang Bio, Inc. Appoints Peter Carney as the Interim Chief Accounting Officer

Insufficient new directors

Mustang Bio, Inc., Annual General Meeting, Jun 21, 2022

Insufficient new directors

Mustang Bio, Inc. Appoints Eliot M. Lurier as Interim Chief Financial Officer

President recently bought €211k worth of stock

Recent updates

Nasdaq Hearings Panel Grants Mustang Bio's Request for an Extension Through January 31, 2025, to Demonstrate Compliance with the Bid Price Rule, and Through February 18, 2025, to Demonstrate Compliance with the Equity Rule

Listing Qualifications Department of Nasdaq Determines to Delist the Mustang Bio's Securities from Nasdaq

Mustang Bio, Inc. has filed a Follow-on Equity Offering in the amount of $2.51299 million.

Mustang Bio, Inc. has completed a Follow-on Equity Offering in the amount of $5.6 million.

Mustang Bio, Inc. Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of Mb-106, Cd20-Targeted Autologous Car-T Therapy

Mustang Bio Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2) for Continued Listing on the Nasdaq Capital Market

Mustang Bio, Inc. has completed a Follow-on Equity Offering in the amount of $3.998428 million.

Mustang Bio, Inc Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases

Mustang Bio Receives Deficiency Letter from Nasdaq Due to Non-Compliance with the Minimum Stockholders’ Equity Requirement Under Nasdaq Listing Rule 5550(b)(1)

Mustang Bio, Inc. has filed a Follow-on Equity Offering in the amount of $10.5 million.

Mustang Bio, Inc. Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101IL13Ra2-targeted CAR T-Cells in High-Grade Glioma

Mustang Bio, Inc. Appoints Peter Carney as the Interim Chief Accounting Officer

Mustang Bio, Inc. announced that it has received $4.742942 million in funding

Mustang Bio, Inc. has completed a Follow-on Equity Offering in the amount of $4.398333 million.

Mustang Bio, Inc. Announces FDA Acceptance of IND Application for MB-109, A Novel Combination of MB-101 (IL13RA2-Targeted Car-T Cell Therapy) and MB-108 (HSV-1 Oncolytic Virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma

Mustang Bio, Inc. Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy

uBriGene (Boston) Biosciences Inc. completed the acquisition of Worcester manufacturing facility of Mustang Bio, Inc.

Mustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy

uBriGene (Boston) Biosciences Inc. entered into asset purchase agreement to acquire Worcester manufacturing facility of Mustang Bio, Inc. for $11 million.

Mustang Bio, Inc. Provides CAR T Cell Therapy Portfolio Updates and 2023 Anticipated Milestones

Insufficient new directors

Mustang Bio Announces First Patient Treated in Its Multicenter Phase 1/2 Clinical Trial of Mb-106, A First-In-Class Cd20-Targeted, Autologous Car T Cell Therapy to Treat B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Mustang Bio Announces First Patient Successfully Treated by Ex Vivo Lentiviral Gene Therapy to Treat Rag1 Severe Combined Immunodeficiency

Mustang Bio, Inc. Announces Updated Interim Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy

Mustang Bio Receives Letter from the Listing Qualifications Staff of Nasdaq

Mustang Bio, Inc. Announces Updated Interim Data on X-Linked Severe Combined Immunodeficiency Treatment with Lentiviral Vector Gene Therapy Support Upcoming Multicenter Pivotal Phase 2 Trial for MB-107

Mustang Bio, Inc. Announces Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy, Selected for Oral Presentation at European Hematology Association 2022 Hybrid Congress

Mustang Bio, Inc. Announces Data on Treatment with Lentiviral Viral Vector Gene Therapy for X-Linked Severe Combined Immunodeficiency Selected for Oral Presentation at American Society of Gene & Cell Therapy 25th Annual Meeting

Mustang Bio, Inc., Annual General Meeting, Jun 21, 2022

Insufficient new directors

Mustang Bio Inc. Announces Updated Interim Phase 1/2 Data for Mb-106, Cd20-Targeted Car T Therapy, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Mustang Bio, Inc. Appoints Eliot M. Lurier as Interim Chief Financial Officer

Mustang Bio, Inc. Announces Phase 1 Clinical Trial Combining MB-101 and MB-108 for the Treatment of Glioblastoma

Mustang Bio Provides an Update on its IND Application for MB-207, a Lentiviral Gene Therapy for Treatment of X-linked Severe Combined Immunodeficiency in Previously Transplanted Patients

Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at the 2022 Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

Mustang Bio Announces MB-101 (IL13Ra2-targeted CAR T cells) Scientific Presentations at Upcoming Virtual Conferences

President recently bought €211k worth of stock

Mustang Bio, Inc. Receives European Medicines Agency PRIME Designation for MB-107 to Treat X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants

Mustang Bio, Inc.(NasdaqGM:MBIO) dropped from Russell 2500 Growth Index

Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 CD20-Targeted CAR T in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia

Mustang Bio and City of Hope Announce First Patient Dosed in Phase 1 Clinical Trial of MB-101 to Treat Leptomeningeal Brain Tumors

Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at European Hematology Association 2021 Virtual Congress

Mustang Bio, Inc. Announces FDA Acceptance of IND Application for MB-106, a CD20-Targeted CAR T Therapy

Key Executive recently sold €56k worth of stock

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş